ALK fusion

News alerts, weekly reports and conference planners

Entrez ID:

238

Related biomarkers:

‹

›

Related tests:

Oncomine™ Dx Target Test (9)

ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2
ALK fusion	Melanoma	ALK fusion	Melanoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK fusion	Melanoma	ALK fusion	Melanoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ALK fusion	Lung Adenocarcinoma	ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK fusion	Colorectal Adenocarcinoma	ALK fusion	Colorectal Adenocarcinoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	pemetrexed Resistant: C3 – Early Trials pemetrexed Resistant : C3	pemetrexed Resistant: C3 – Early Trials pemetrexed Resistant : C3
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	bevacizumab + alectinib Sensitive: C3 – Early Trials bevacizumab + alectinib Sensitive : C3	bevacizumab + alectinib Sensitive: C3 – Early Trials bevacizumab + alectinib Sensitive : C3
ALK fusion	Lung Cancer	ALK fusion	Lung Cancer	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3
ALK fusion	Lung Adenocarcinoma	ALK fusion	Lung Adenocarcinoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK fusion	Glioma	ALK fusion	Glioma	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4
ALK fusion	Triple Negative Breast Cancer	ALK fusion	Triple Negative Breast Cancer	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK fusion	T Cell Non-Hodgkin Lymphoma	ALK fusion	T Cell Non-Hodgkin Lymphoma	gilteritinib Sensitive: D – Preclinical gilteritinib Sensitive : D	gilteritinib Sensitive: D – Preclinical gilteritinib Sensitive : D

ALK fusion

Associations